Thyroid Cancer Awareness month has been observed worldwide since its initiation in 2000 by the Thyroid Cancer Survivors’ Association.
HemOnc Today presents seven updates in thyroid cancer research to help promote early detection and treatment strategies in your practice.
- The annual incidence of thyroid cancer, which rapidly increased over the last 3 decades, appears to have leveled off after 2009, according to results of a SEER analysis. Read more.
- The BRAF kinase inhibitor vemurafenib (Zelboraf, Genentech) demonstrated antitumor activity in patients with BRAF V600E–positive papillary thyroid cancer that is refractory to radioactive iodine, according to the results of an open-label, multicenter phase 2 trial. Read more.
, MD, PhD, professor of pathology at University of Pittsburgh Medical Center, discusses a new entity in thyroid pathology — noninvasive follicular thyroid neoplasm. Watch here.
- The WHO’s International Agency for Research on Cancer working group identified an additional eight types of cancer associated with excess body fatness — including cancers of the thyroid. Read more.
- Noninvasive thyroid tumors currently diagnosed as encapsulated follicular variant of papillary thyroid carcinoma had a very low probability of adverse outcomes and should no longer be classified as a cancer, according to researchers of a retrospective study. Read more.
Gregory W. Randolph, MD, FACS, FACE, the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology at Harvard Medical School and President of the American Academy of Otolaryngology – Head and Neck Surgery, discusses his presentation on the surgical approaches to low-risk thyroid cancer. Watch here.
- Registries that include extent of surgical procedure may frequently inaccurately code total thyroidectomy as thyroid lobectomy, according to a retrospective analysis of the Tennessee Cancer Registry presented during the plenary session of the Society for Surgical Oncology’s Annual Cancer Symposium. Read more.